BB BIOTECH AG was founded in Switzerland in November 1993 as an investment company and invests in biotech companies globally.
BB BIOTECH has meanwhile become one of the largest pure play biotech investors. BB BIOTECH registered shares are listed on the Swiss Stock Market, in the "TecDAX" in Germany and the Italian "Star Segment".

The biotech industry is one of the most interesting growth industries of all. The increasing aging population and the many diseases that still can't be cured or treated increases the demand for new drugs. Due to the research of the biotech industry in the last years, an increasing number of innovative substances with therapeutic potential have been developed.

The growth of the biotech industry is driven by more than 250 products in Phase lll, the last phase of clinical development. Since the year 2000, more than one half of all newly approved drugs, a total of 20 to 30 per year, have been discovered by biotech companies. Total sales of biotech drugs will grow accordingly and an increasing number of biotech companies will turn profitable. BB BIOTECH offers its shareholders the opportunity to participate in this growth with above-average appreciation potential.